Document Detail

Export of pharmaceuticals and medical devices under the federal Food, Drug & Cosmetic Act: FDA's striking change in interpretation post-Shelhigh.
MedLine Citation:
PMID:  19998744     Owner:  HSR     Status:  MEDLINE    
With no communication to industry except court filings in United States v. Undetermined Quantities of Boxes of Articles of Device (Shelhigh) and a draft guidance document, the Food and Drug Administration (FDA) has articulated new policies regarding export of pharmaceutical products and medical devices. FDA's departure from its historic interpretation of the export provisions of the Federal Food, Drug, and Cosmetic Act (FDCA) significantly limits the ability of manufacturers to export misbranded drugs and medical devices that FDA deems "adulterated," contrary to the plain language and legislative intent of the FDCA. To further exacerbate the issue, FDA has begun to implement these policies without the notice-and-comment rulemaking required by the Administrative Procedures Act (APA), but rather through an enforcement proceeding brought in the United States District Court for the District of New Jersey. In a letter opinion, the District Court prevented the export of Current Good Manufacturing Practices (CGMP) --adulterated medical devices that complied with FDCA Section 801(e)(1), at least as historically interpreted by FDA. The purpose of this article is to review the history of FDA's export policies for pharmaceuticals and medical devices, particularly those aspects of the export policies that are affected by FDA's recent change in position. Three changes in FDA's interpretation of the export provisions of the FDCA will be addressed: 1) unapproved devices that a manufacturer reasonably believes are eligible for Section 510(k) clearance may no longer be exported under Section 801(e) and now must be exported under Section 802, in substantial compliance with Current CGMP; 2) adulterated devices and misbranded drugs can only be exported if the foreign purchaser's specifications cause the product to be adulterated; and 3) an article may not be exported if a like article has ever been sold or offered for sale in domestic commerce. FDA's new interpretations of FDCA Sections 801 and 802 are not valid interpretations of these statutory provisions. Although FDA always exercised its enforcement discretion under the FDCA with respect to export of an unapproved device that a manufacturer reasonably believed to be eligible for Section 510(k) clearance, FDA's recent shift in interpretation contravenes its longstanding approach without sufficient public notice.
Edward M Basile; Deborah Tolomeo; Elizabeth Gluck
Related Documents :
10182694 - Medical device reporting: manufacturer reporting, importer reporting, user facility rep...
14624844 - The morphogen sonic hedgehog collaborates with netrin-1 to guide axons in the spinal cord.
19998744 - Export of pharmaceuticals and medical devices under the federal food, drug & cosmetic a...
18977384 - Withdrawn: book review: biofilms in the food environment, h.p. blaschek, h.h. wang, m.e...
19427214 - The global stock of domesticated honey bees is growing slower than agricultural demand ...
11545224 - Observation of everyday hand-washing behavior of japanese, and effects of antibacterial...
Publication Detail:
Type:  Historical Article; Journal Article    
Journal Detail:
Title:  Food and drug law journal     Volume:  64     ISSN:  1064-590X     ISO Abbreviation:  Food Drug Law J     Publication Date:  2009  
Date Detail:
Created Date:  2009-12-10     Completed Date:  2009-12-22     Revised Date:  2010-01-13    
Medline Journal Info:
Nlm Unique ID:  9215384     Medline TA:  Food Drug Law J     Country:  United States    
Other Details:
Languages:  eng     Pagination:  149-69     Citation Subset:  T    
King & Spalding, Washington, DC, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Commerce / legislation & jurisprudence*
Device Approval / legislation & jurisprudence*
Drug Approval / legislation & jurisprudence*
Equipment and Supplies
Government Regulation
Guidelines as Topic
History, 20th Century
Legislation, Drug / history,  organization & administration*
Pharmaceutical Preparations
United States
United States Food and Drug Administration
Reg. No./Substance:
0/Pharmaceutical Preparations

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  No longer "if," but "when": the coming abbreviated approval pathway for follow-on biologics.
Next Document:  Analysis of the impact of the Uruguay Round Agreements Act on pharmaceutical patents.